News for Healthier Living

Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial

For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase 1b trial led by researchers at The University of Texas MD Anderson Cancer Center, supporting an approach to selecting treatments based on the structural features of uncommon EGFR mutations.

October 16, 2026


October 16 2026

October 15 2026

October 14 2026

October 13 2026

October 12 2026

October 11 2026

October 10 2026

October 9 2026

October 8 2026

October 7 2026

October 6 2026

October 5 2026